Heparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarction

Basit Öğe Kaydı
dc.contributor.authorGurbuz, Ahmet Seyfeddin
dc.contributor.authorOzturk, Semi
dc.contributor.authorEfe, Suleyman Cagan
dc.contributor.authorYilmaz, Mehmet Fatih
dc.contributor.authorYanik, Raziye Ecem
dc.contributor.authorYaman, Ali
dc.contributor.authorKirma, Cevat
dc.date.accessioned2024-02-23T14:20:32Z
dc.date.available2024-02-23T14:20:32Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractObjective: Heparanase (HPA) is an endo-beta-D-glucuronidase capable of degrading heparin sulphate (HS) and heparin side chains. HPA plays a role in tumour growth, angiogenesis, cell invasion and in activation of the coagulation system. We aimed to investigate the relationship between HPA and thrombus burden (TB) in patients with ST-Segment Elevation Myocardial Infarction (STEMI). Methods: This prospective study enrolled 187 patients with STEMI who were treated with primary percutaneous coronary intervention (pPCI). Blood samples were taken to determine serum HPA levels prior to coronary angiography and heparin administration. Serum HPA analysis was performed with a commercially available Human Elisa kit. Results: Patients were divided into two groups: high TB (n:58) and low TB (n:129) group. Serum HPA levels were significantly higher in patients with high TB than low TB [250.1 (188.5-338.1) vs. 173.6 (134.3-219.8) pg/mL] (p < 0.001). Serum HPA levels were higher in patients with no-reflow phenomenon compared with others [(409.3 (375.6-512.5) pg/mL vs. 186.2 (144.2-247.4) pg/mL, p < 0.001]. In multiple logistic regression analysis HPA was a predictor of high TB. Conclusion: Elevated HPA level in patients with STEMI is related to high TB. Furthermore, increased HPA level may be associated with thrombotic complications such as no-reflow phenomenon in patients with STEMI.en_US
dc.identifier.doi10.1080/1354750X.2019.1628809
dc.identifier.endpage606en_US
dc.identifier.issn1354-750X
dc.identifier.issn1366-5804
dc.identifier.issue6en_US
dc.identifier.pmid31215255en_US
dc.identifier.scopus2-s2.0-85067660395en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage600en_US
dc.identifier.urihttps://doi.org/10.1080/1354750X.2019.1628809
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13200
dc.identifier.volume24en_US
dc.identifier.wosWOS:000472418500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBiomarkersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtherosclerosisen_US
dc.subjectHeparanaseen_US
dc.subjectMyocardial Infarctionen_US
dc.subjectThrombosisen_US
dc.subjectNo-Reflowen_US
dc.titleHeparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu